Global Secondary Progressive Multiple Sclerosis Drug Market Growth 2025-2031
The global Secondary Progressive Multiple Sclerosis Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Secondary Progressive Multiple Sclerosis Drug Industry Forecast? looks at past sales and reviews total world Secondary Progressive Multiple Sclerosis Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Secondary Progressive Multiple Sclerosis Drug sales for 2025 through 2031. With Secondary Progressive Multiple Sclerosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Secondary Progressive Multiple Sclerosis Drug industry.
This Insight Report provides a comprehensive analysis of the global Secondary Progressive Multiple Sclerosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Secondary Progressive Multiple Sclerosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Secondary Progressive Multiple Sclerosis Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Secondary Progressive Multiple Sclerosis Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Secondary Progressive Multiple Sclerosis Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Secondary Progressive Multiple Sclerosis Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
What is the 10-year outlook for the global Secondary Progressive Multiple Sclerosis Drug market?
What factors are driving Secondary Progressive Multiple Sclerosis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Secondary Progressive Multiple Sclerosis Drug market opportunities vary by end market size?
How does Secondary Progressive Multiple Sclerosis Drug break out by Type, by Application?
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the ?Secondary Progressive Multiple Sclerosis Drug Industry Forecast? looks at past sales and reviews total world Secondary Progressive Multiple Sclerosis Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Secondary Progressive Multiple Sclerosis Drug sales for 2025 through 2031. With Secondary Progressive Multiple Sclerosis Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Secondary Progressive Multiple Sclerosis Drug industry.
This Insight Report provides a comprehensive analysis of the global Secondary Progressive Multiple Sclerosis Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Secondary Progressive Multiple Sclerosis Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Secondary Progressive Multiple Sclerosis Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Secondary Progressive Multiple Sclerosis Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Secondary Progressive Multiple Sclerosis Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Secondary Progressive Multiple Sclerosis Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Inebilizumab
- GLX-1112
- DC-TAB
- Etomoxir
- IB-MS
- Others
- Hospital
- Clinic
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- AB Science SA
- Actelion Ltd
- Biogen, Inc.
- F. Hoffmann-La Roche Ltd.
- Genzyme Corporation
- Glialogix, Inc.
- Immune Response BioPharma, Inc.
- Innate Immunotherapeutics Ltd
- Kyorin Pharmaceutical Co., Ltd.
- Mallinckrodt Plc
- MedDay SA
- MedImmune, LLC
- Merck KGaA
- Meta-IQ ApS
- Novartis AG
- Opexa Therapeutics, Inc.
- Xenetic Biosciences (UK) Limited
What is the 10-year outlook for the global Secondary Progressive Multiple Sclerosis Drug market?
What factors are driving Secondary Progressive Multiple Sclerosis Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Secondary Progressive Multiple Sclerosis Drug market opportunities vary by end market size?
How does Secondary Progressive Multiple Sclerosis Drug break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Country/Region, 2020, 2024 & 2031
2.2 Secondary Progressive Multiple Sclerosis Drug Segment by Type
2.2.1 Inebilizumab
2.2.2 GLX-1112
2.2.3 DC-TAB
2.2.4 Etomoxir
2.2.5 IB-MS
2.2.6 Others
2.3 Secondary Progressive Multiple Sclerosis Drug Sales by Type
2.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Type (2020-2025)
2.4 Secondary Progressive Multiple Sclerosis Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Secondary Progressive Multiple Sclerosis Drug Sales by Application
2.5.1 Global Secondary Progressive Multiple Sclerosis Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Secondary Progressive Multiple Sclerosis Drug Breakdown Data by Company
3.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Company (2020-2025)
3.1.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2020-2025)
3.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2020-2025)
3.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2020-2025)
3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Company
3.4 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Location Distribution
3.4.2 Players Secondary Progressive Multiple Sclerosis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales Growth
4.4 APAC Secondary Progressive Multiple Sclerosis Drug Sales Growth
4.5 Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth
4.6 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth
5 AMERICAS
5.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country
5.1.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025)
5.1.2 Americas Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025)
5.2 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025)
5.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region
6.1.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region (2020-2025)
6.1.2 APAC Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2020-2025)
6.2 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025)
6.3 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Secondary Progressive Multiple Sclerosis Drug by Country
7.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025)
7.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025)
7.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025)
7.3 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug by Country
8.1.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug
10.3 Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
10.4 Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Secondary Progressive Multiple Sclerosis Drug Distributors
11.3 Secondary Progressive Multiple Sclerosis Drug Customer
12 WORLD FORECAST REVIEW FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG BY GEOGRAPHIC REGION
12.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Region
12.1.1 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Region (2026-2031)
12.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Type (2026-2031)
12.7 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 AB Science SA
13.1.1 AB Science SA Company Information
13.1.2 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 AB Science SA Main Business Overview
13.1.5 AB Science SA Latest Developments
13.2 Actelion Ltd
13.2.1 Actelion Ltd Company Information
13.2.2 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Actelion Ltd Main Business Overview
13.2.5 Actelion Ltd Latest Developments
13.3 Biogen, Inc.
13.3.1 Biogen, Inc. Company Information
13.3.2 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Biogen, Inc. Main Business Overview
13.3.5 Biogen, Inc. Latest Developments
13.4 F. Hoffmann-La Roche Ltd.
13.4.1 F. Hoffmann-La Roche Ltd. Company Information
13.4.2 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 F. Hoffmann-La Roche Ltd. Main Business Overview
13.4.5 F. Hoffmann-La Roche Ltd. Latest Developments
13.5 Genzyme Corporation
13.5.1 Genzyme Corporation Company Information
13.5.2 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Genzyme Corporation Main Business Overview
13.5.5 Genzyme Corporation Latest Developments
13.6 Glialogix, Inc.
13.6.1 Glialogix, Inc. Company Information
13.6.2 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Glialogix, Inc. Main Business Overview
13.6.5 Glialogix, Inc. Latest Developments
13.7 Immune Response BioPharma, Inc.
13.7.1 Immune Response BioPharma, Inc. Company Information
13.7.2 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Immune Response BioPharma, Inc. Main Business Overview
13.7.5 Immune Response BioPharma, Inc. Latest Developments
13.8 Innate Immunotherapeutics Ltd
13.8.1 Innate Immunotherapeutics Ltd Company Information
13.8.2 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Innate Immunotherapeutics Ltd Main Business Overview
13.8.5 Innate Immunotherapeutics Ltd Latest Developments
13.9 Kyorin Pharmaceutical Co., Ltd.
13.9.1 Kyorin Pharmaceutical Co., Ltd. Company Information
13.9.2 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Kyorin Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Kyorin Pharmaceutical Co., Ltd. Latest Developments
13.10 Mallinckrodt Plc
13.10.1 Mallinckrodt Plc Company Information
13.10.2 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Mallinckrodt Plc Main Business Overview
13.10.5 Mallinckrodt Plc Latest Developments
13.11 MedDay SA
13.11.1 MedDay SA Company Information
13.11.2 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.11.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 MedDay SA Main Business Overview
13.11.5 MedDay SA Latest Developments
13.12 MedImmune, LLC
13.12.1 MedImmune, LLC Company Information
13.12.2 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.12.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 MedImmune, LLC Main Business Overview
13.12.5 MedImmune, LLC Latest Developments
13.13 Merck KGaA
13.13.1 Merck KGaA Company Information
13.13.2 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.13.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Merck KGaA Main Business Overview
13.13.5 Merck KGaA Latest Developments
13.14 Meta-IQ ApS
13.14.1 Meta-IQ ApS Company Information
13.14.2 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.14.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Meta-IQ ApS Main Business Overview
13.14.5 Meta-IQ ApS Latest Developments
13.15 Novartis AG
13.15.1 Novartis AG Company Information
13.15.2 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.15.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Novartis AG Main Business Overview
13.15.5 Novartis AG Latest Developments
13.16 Opexa Therapeutics, Inc.
13.16.1 Opexa Therapeutics, Inc. Company Information
13.16.2 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.16.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Opexa Therapeutics, Inc. Main Business Overview
13.16.5 Opexa Therapeutics, Inc. Latest Developments
13.17 Xenetic Biosciences (UK) Limited
13.17.1 Xenetic Biosciences (UK) Limited Company Information
13.17.2 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.17.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Xenetic Biosciences (UK) Limited Main Business Overview
13.17.5 Xenetic Biosciences (UK) Limited Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Secondary Progressive Multiple Sclerosis Drug by Country/Region, 2020, 2024 & 2031
2.2 Secondary Progressive Multiple Sclerosis Drug Segment by Type
2.2.1 Inebilizumab
2.2.2 GLX-1112
2.2.3 DC-TAB
2.2.4 Etomoxir
2.2.5 IB-MS
2.2.6 Others
2.3 Secondary Progressive Multiple Sclerosis Drug Sales by Type
2.3.1 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Type (2020-2025)
2.4 Secondary Progressive Multiple Sclerosis Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Secondary Progressive Multiple Sclerosis Drug Sales by Application
2.5.1 Global Secondary Progressive Multiple Sclerosis Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Application (2020-2025)
3 GLOBAL BY COMPANY
3.1 Global Secondary Progressive Multiple Sclerosis Drug Breakdown Data by Company
3.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Company (2020-2025)
3.1.2 Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2020-2025)
3.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2020-2025)
3.2.2 Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2020-2025)
3.3 Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Company
3.4 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Product Location Distribution
3.4.2 Players Secondary Progressive Multiple Sclerosis Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG BY GEOGRAPHIC REGION
4.1 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Secondary Progressive Multiple Sclerosis Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Secondary Progressive Multiple Sclerosis Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales Growth
4.4 APAC Secondary Progressive Multiple Sclerosis Drug Sales Growth
4.5 Europe Secondary Progressive Multiple Sclerosis Drug Sales Growth
4.6 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Growth
5 AMERICAS
5.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country
5.1.1 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025)
5.1.2 Americas Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025)
5.2 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025)
5.3 Americas Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region
6.1.1 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region (2020-2025)
6.1.2 APAC Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2020-2025)
6.2 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025)
6.3 APAC Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Secondary Progressive Multiple Sclerosis Drug by Country
7.1.1 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025)
7.1.2 Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025)
7.2 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025)
7.3 Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug by Country
8.1.1 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug
10.3 Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
10.4 Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Secondary Progressive Multiple Sclerosis Drug Distributors
11.3 Secondary Progressive Multiple Sclerosis Drug Customer
12 WORLD FORECAST REVIEW FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG BY GEOGRAPHIC REGION
12.1 Global Secondary Progressive Multiple Sclerosis Drug Market Size Forecast by Region
12.1.1 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Region (2026-2031)
12.1.2 Global Secondary Progressive Multiple Sclerosis Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Type (2026-2031)
12.7 Global Secondary Progressive Multiple Sclerosis Drug Forecast by Application (2026-2031)
13 KEY PLAYERS ANALYSIS
13.1 AB Science SA
13.1.1 AB Science SA Company Information
13.1.2 AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.1.3 AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 AB Science SA Main Business Overview
13.1.5 AB Science SA Latest Developments
13.2 Actelion Ltd
13.2.1 Actelion Ltd Company Information
13.2.2 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.2.3 Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Actelion Ltd Main Business Overview
13.2.5 Actelion Ltd Latest Developments
13.3 Biogen, Inc.
13.3.1 Biogen, Inc. Company Information
13.3.2 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.3.3 Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Biogen, Inc. Main Business Overview
13.3.5 Biogen, Inc. Latest Developments
13.4 F. Hoffmann-La Roche Ltd.
13.4.1 F. Hoffmann-La Roche Ltd. Company Information
13.4.2 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.4.3 F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 F. Hoffmann-La Roche Ltd. Main Business Overview
13.4.5 F. Hoffmann-La Roche Ltd. Latest Developments
13.5 Genzyme Corporation
13.5.1 Genzyme Corporation Company Information
13.5.2 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.5.3 Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Genzyme Corporation Main Business Overview
13.5.5 Genzyme Corporation Latest Developments
13.6 Glialogix, Inc.
13.6.1 Glialogix, Inc. Company Information
13.6.2 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.6.3 Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 Glialogix, Inc. Main Business Overview
13.6.5 Glialogix, Inc. Latest Developments
13.7 Immune Response BioPharma, Inc.
13.7.1 Immune Response BioPharma, Inc. Company Information
13.7.2 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.7.3 Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Immune Response BioPharma, Inc. Main Business Overview
13.7.5 Immune Response BioPharma, Inc. Latest Developments
13.8 Innate Immunotherapeutics Ltd
13.8.1 Innate Immunotherapeutics Ltd Company Information
13.8.2 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.8.3 Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Innate Immunotherapeutics Ltd Main Business Overview
13.8.5 Innate Immunotherapeutics Ltd Latest Developments
13.9 Kyorin Pharmaceutical Co., Ltd.
13.9.1 Kyorin Pharmaceutical Co., Ltd. Company Information
13.9.2 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.9.3 Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Kyorin Pharmaceutical Co., Ltd. Main Business Overview
13.9.5 Kyorin Pharmaceutical Co., Ltd. Latest Developments
13.10 Mallinckrodt Plc
13.10.1 Mallinckrodt Plc Company Information
13.10.2 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.10.3 Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Mallinckrodt Plc Main Business Overview
13.10.5 Mallinckrodt Plc Latest Developments
13.11 MedDay SA
13.11.1 MedDay SA Company Information
13.11.2 MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.11.3 MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 MedDay SA Main Business Overview
13.11.5 MedDay SA Latest Developments
13.12 MedImmune, LLC
13.12.1 MedImmune, LLC Company Information
13.12.2 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.12.3 MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 MedImmune, LLC Main Business Overview
13.12.5 MedImmune, LLC Latest Developments
13.13 Merck KGaA
13.13.1 Merck KGaA Company Information
13.13.2 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.13.3 Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 Merck KGaA Main Business Overview
13.13.5 Merck KGaA Latest Developments
13.14 Meta-IQ ApS
13.14.1 Meta-IQ ApS Company Information
13.14.2 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.14.3 Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Meta-IQ ApS Main Business Overview
13.14.5 Meta-IQ ApS Latest Developments
13.15 Novartis AG
13.15.1 Novartis AG Company Information
13.15.2 Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.15.3 Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Novartis AG Main Business Overview
13.15.5 Novartis AG Latest Developments
13.16 Opexa Therapeutics, Inc.
13.16.1 Opexa Therapeutics, Inc. Company Information
13.16.2 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.16.3 Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 Opexa Therapeutics, Inc. Main Business Overview
13.16.5 Opexa Therapeutics, Inc. Latest Developments
13.17 Xenetic Biosciences (UK) Limited
13.17.1 Xenetic Biosciences (UK) Limited Company Information
13.17.2 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
13.17.3 Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 Xenetic Biosciences (UK) Limited Main Business Overview
13.17.5 Xenetic Biosciences (UK) Limited Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Secondary Progressive Multiple Sclerosis Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Secondary Progressive Multiple Sclerosis Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Inebilizumab
Table 4. Major Players of GLX-1112
Table 5. Major Players of DC-TAB
Table 6. Major Players of Etomoxir
Table 7. Major Players of IB-MS
Table 8. Major Players of Others
Table 9. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 10. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Table 11. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2020-2025) & ($ million)
Table 12. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2020-2025)
Table 13. Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 14. Global Secondary Progressive Multiple Sclerosis Drug Sale by Application (2020-2025) & (K Pcs)
Table 15. Global Secondary Progressive Multiple Sclerosis Drug Sale Market Share by Application (2020-2025)
Table 16. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2020-2025) & ($ million)
Table 17. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2020-2025)
Table 18. Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 19. Global Secondary Progressive Multiple Sclerosis Drug Sales by Company (2020-2025) & (K Pcs)
Table 20. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2020-2025)
Table 21. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2020-2025) & ($ millions)
Table 22. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2020-2025)
Table 23. Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 24. Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Producing Area Distribution and Sales Area
Table 25. Players Secondary Progressive Multiple Sclerosis Drug Products Offered
Table 26. Secondary Progressive Multiple Sclerosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Secondary Progressive Multiple Sclerosis Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 30. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Geographic Region (2020-2025)
Table 31. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global Secondary Progressive Multiple Sclerosis Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 34. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country/Region (2020-2025)
Table 35. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 38. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2020-2025)
Table 39. Americas Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 41. Americas Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) & (K Pcs)
Table 42. APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region (2020-2025) & (K Pcs)
Table 43. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2020-2025)
Table 44. APAC Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 46. APAC Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) & (K Pcs)
Table 47. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 48. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 50. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) & (K Pcs)
Table 55. Key Market Drivers & Growth Opportunities of Secondary Progressive Multiple Sclerosis Drug
Table 56. Key Market Challenges & Risks of Secondary Progressive Multiple Sclerosis Drug
Table 57. Key Industry Trends of Secondary Progressive Multiple Sclerosis Drug
Table 58. Secondary Progressive Multiple Sclerosis Drug Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Secondary Progressive Multiple Sclerosis Drug Distributors List
Table 61. Secondary Progressive Multiple Sclerosis Drug Customer List
Table 62. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 63. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Americas Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 65. Americas Secondary Progressive Multiple Sclerosis Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. APAC Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 67. APAC Secondary Progressive Multiple Sclerosis Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 68. Europe Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 69. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 71. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 72. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 73. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 74. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 75. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 76. AB Science SA Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 77. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 78. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 79. AB Science SA Main Business
Table 80. AB Science SA Latest Developments
Table 81. Actelion Ltd Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 82. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 83. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 84. Actelion Ltd Main Business
Table 85. Actelion Ltd Latest Developments
Table 86. Biogen, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 87. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 88. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 89. Biogen, Inc. Main Business
Table 90. Biogen, Inc. Latest Developments
Table 91. F. Hoffmann-La Roche Ltd. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 92. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 93. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 94. F. Hoffmann-La Roche Ltd. Main Business
Table 95. F. Hoffmann-La Roche Ltd. Latest Developments
Table 96. Genzyme Corporation Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 98. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 99. Genzyme Corporation Main Business
Table 100. Genzyme Corporation Latest Developments
Table 101. Glialogix, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 102. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 103. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 104. Glialogix, Inc. Main Business
Table 105. Glialogix, Inc. Latest Developments
Table 106. Immune Response BioPharma, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 107. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 108. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 109. Immune Response BioPharma, Inc. Main Business
Table 110. Immune Response BioPharma, Inc. Latest Developments
Table 111. Innate Immunotherapeutics Ltd Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 112. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 113. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 114. Innate Immunotherapeutics Ltd Main Business
Table 115. Innate Immunotherapeutics Ltd Latest Developments
Table 116. Kyorin Pharmaceutical Co., Ltd. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 117. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 118. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 119. Kyorin Pharmaceutical Co., Ltd. Main Business
Table 120. Kyorin Pharmaceutical Co., Ltd. Latest Developments
Table 121. Mallinckrodt Plc Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 122. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 123. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 124. Mallinckrodt Plc Main Business
Table 125. Mallinckrodt Plc Latest Developments
Table 126. MedDay SA Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 127. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 128. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 129. MedDay SA Main Business
Table 130. MedDay SA Latest Developments
Table 131. MedImmune, LLC Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 132. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 133. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 134. MedImmune, LLC Main Business
Table 135. MedImmune, LLC Latest Developments
Table 136. Merck KGaA Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 137. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 138. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 139. Merck KGaA Main Business
Table 140. Merck KGaA Latest Developments
Table 141. Meta-IQ ApS Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 142. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 143. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 144. Meta-IQ ApS Main Business
Table 145. Meta-IQ ApS Latest Developments
Table 146. Novartis AG Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 147. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 148. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 149. Novartis AG Main Business
Table 150. Novartis AG Latest Developments
Table 151. Opexa Therapeutics, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 152. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 153. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 154. Opexa Therapeutics, Inc. Main Business
Table 155. Opexa Therapeutics, Inc. Latest Developments
Table 156. Xenetic Biosciences (UK) Limited Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 157. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 158. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 159. Xenetic Biosciences (UK) Limited Main Business
Table 160. Xenetic Biosciences (UK) Limited Latest Developments
Table 1. Secondary Progressive Multiple Sclerosis Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Secondary Progressive Multiple Sclerosis Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of Inebilizumab
Table 4. Major Players of GLX-1112
Table 5. Major Players of DC-TAB
Table 6. Major Players of Etomoxir
Table 7. Major Players of IB-MS
Table 8. Major Players of Others
Table 9. Global Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 10. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Table 11. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Type (2020-2025) & ($ million)
Table 12. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2020-2025)
Table 13. Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 14. Global Secondary Progressive Multiple Sclerosis Drug Sale by Application (2020-2025) & (K Pcs)
Table 15. Global Secondary Progressive Multiple Sclerosis Drug Sale Market Share by Application (2020-2025)
Table 16. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Application (2020-2025) & ($ million)
Table 17. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application (2020-2025)
Table 18. Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 19. Global Secondary Progressive Multiple Sclerosis Drug Sales by Company (2020-2025) & (K Pcs)
Table 20. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company (2020-2025)
Table 21. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Company (2020-2025) & ($ millions)
Table 22. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company (2020-2025)
Table 23. Global Secondary Progressive Multiple Sclerosis Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 24. Key Manufacturers Secondary Progressive Multiple Sclerosis Drug Producing Area Distribution and Sales Area
Table 25. Players Secondary Progressive Multiple Sclerosis Drug Products Offered
Table 26. Secondary Progressive Multiple Sclerosis Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Secondary Progressive Multiple Sclerosis Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 30. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Geographic Region (2020-2025)
Table 31. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global Secondary Progressive Multiple Sclerosis Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 34. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country/Region (2020-2025)
Table 35. Global Secondary Progressive Multiple Sclerosis Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 38. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2020-2025)
Table 39. Americas Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 41. Americas Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) & (K Pcs)
Table 42. APAC Secondary Progressive Multiple Sclerosis Drug Sales by Region (2020-2025) & (K Pcs)
Table 43. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region (2020-2025)
Table 44. APAC Secondary Progressive Multiple Sclerosis Drug Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 46. APAC Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) & (K Pcs)
Table 47. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 48. Europe Secondary Progressive Multiple Sclerosis Drug Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 50. Europe Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Country (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Type (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales by Application (2020-2025) & (K Pcs)
Table 55. Key Market Drivers & Growth Opportunities of Secondary Progressive Multiple Sclerosis Drug
Table 56. Key Market Challenges & Risks of Secondary Progressive Multiple Sclerosis Drug
Table 57. Key Industry Trends of Secondary Progressive Multiple Sclerosis Drug
Table 58. Secondary Progressive Multiple Sclerosis Drug Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Secondary Progressive Multiple Sclerosis Drug Distributors List
Table 61. Secondary Progressive Multiple Sclerosis Drug Customer List
Table 62. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 63. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Americas Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 65. Americas Secondary Progressive Multiple Sclerosis Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. APAC Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 67. APAC Secondary Progressive Multiple Sclerosis Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 68. Europe Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 69. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 71. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 72. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 73. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 74. Global Secondary Progressive Multiple Sclerosis Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 75. Global Secondary Progressive Multiple Sclerosis Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 76. AB Science SA Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 77. AB Science SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 78. AB Science SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 79. AB Science SA Main Business
Table 80. AB Science SA Latest Developments
Table 81. Actelion Ltd Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 82. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 83. Actelion Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 84. Actelion Ltd Main Business
Table 85. Actelion Ltd Latest Developments
Table 86. Biogen, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 87. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 88. Biogen, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 89. Biogen, Inc. Main Business
Table 90. Biogen, Inc. Latest Developments
Table 91. F. Hoffmann-La Roche Ltd. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 92. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 93. F. Hoffmann-La Roche Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 94. F. Hoffmann-La Roche Ltd. Main Business
Table 95. F. Hoffmann-La Roche Ltd. Latest Developments
Table 96. Genzyme Corporation Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 98. Genzyme Corporation Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 99. Genzyme Corporation Main Business
Table 100. Genzyme Corporation Latest Developments
Table 101. Glialogix, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 102. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 103. Glialogix, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 104. Glialogix, Inc. Main Business
Table 105. Glialogix, Inc. Latest Developments
Table 106. Immune Response BioPharma, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 107. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 108. Immune Response BioPharma, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 109. Immune Response BioPharma, Inc. Main Business
Table 110. Immune Response BioPharma, Inc. Latest Developments
Table 111. Innate Immunotherapeutics Ltd Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 112. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 113. Innate Immunotherapeutics Ltd Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 114. Innate Immunotherapeutics Ltd Main Business
Table 115. Innate Immunotherapeutics Ltd Latest Developments
Table 116. Kyorin Pharmaceutical Co., Ltd. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 117. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 118. Kyorin Pharmaceutical Co., Ltd. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 119. Kyorin Pharmaceutical Co., Ltd. Main Business
Table 120. Kyorin Pharmaceutical Co., Ltd. Latest Developments
Table 121. Mallinckrodt Plc Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 122. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 123. Mallinckrodt Plc Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 124. Mallinckrodt Plc Main Business
Table 125. Mallinckrodt Plc Latest Developments
Table 126. MedDay SA Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 127. MedDay SA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 128. MedDay SA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 129. MedDay SA Main Business
Table 130. MedDay SA Latest Developments
Table 131. MedImmune, LLC Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 132. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 133. MedImmune, LLC Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 134. MedImmune, LLC Main Business
Table 135. MedImmune, LLC Latest Developments
Table 136. Merck KGaA Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 137. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 138. Merck KGaA Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 139. Merck KGaA Main Business
Table 140. Merck KGaA Latest Developments
Table 141. Meta-IQ ApS Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 142. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 143. Meta-IQ ApS Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 144. Meta-IQ ApS Main Business
Table 145. Meta-IQ ApS Latest Developments
Table 146. Novartis AG Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 147. Novartis AG Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 148. Novartis AG Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 149. Novartis AG Main Business
Table 150. Novartis AG Latest Developments
Table 151. Opexa Therapeutics, Inc. Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 152. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 153. Opexa Therapeutics, Inc. Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 154. Opexa Therapeutics, Inc. Main Business
Table 155. Opexa Therapeutics, Inc. Latest Developments
Table 156. Xenetic Biosciences (UK) Limited Basic Information, Secondary Progressive Multiple Sclerosis Drug Manufacturing Base, Sales Area and Its Competitors
Table 157. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Product Portfolios and Specifications
Table 158. Xenetic Biosciences (UK) Limited Secondary Progressive Multiple Sclerosis Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 159. Xenetic Biosciences (UK) Limited Main Business
Table 160. Xenetic Biosciences (UK) Limited Latest Developments
LIST OF FIGURES
Figure 1. Picture of Secondary Progressive Multiple Sclerosis Drug
Figure 2. Secondary Progressive Multiple Sclerosis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Secondary Progressive Multiple Sclerosis Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country/Region (2024)
Figure 10. Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Inebilizumab
Figure 12. Product Picture of GLX-1112
Figure 13. Product Picture of DC-TAB
Figure 14. Product Picture of Etomoxir
Figure 15. Product Picture of IB-MS
Figure 16. Product Picture of Others
Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2025
Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2020-2025)
Figure 19. Secondary Progressive Multiple Sclerosis Drug Consumed in Hospital
Figure 20. Global Secondary Progressive Multiple Sclerosis Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 21. Secondary Progressive Multiple Sclerosis Drug Consumed in Clinic
Figure 22. Global Secondary Progressive Multiple Sclerosis Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 23. Secondary Progressive Multiple Sclerosis Drug Consumed in Others
Figure 24. Global Secondary Progressive Multiple Sclerosis Drug Market: Others (2020-2025) & (K Pcs)
Figure 25. Global Secondary Progressive Multiple Sclerosis Drug Sale Market Share by Application (2024)
Figure 26. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application in 2025
Figure 27. Secondary Progressive Multiple Sclerosis Drug Sales by Company in 2025 (K Pcs)
Figure 28. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company in 2025
Figure 29. Secondary Progressive Multiple Sclerosis Drug Revenue by Company in 2025 ($ millions)
Figure 30. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company in 2025
Figure 31. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Secondary Progressive Multiple Sclerosis Drug Sales 2020-2025 (K Pcs)
Figure 34. Americas Secondary Progressive Multiple Sclerosis Drug Revenue 2020-2025 ($ millions)
Figure 35. APAC Secondary Progressive Multiple Sclerosis Drug Sales 2020-2025 (K Pcs)
Figure 36. APAC Secondary Progressive Multiple Sclerosis Drug Revenue 2020-2025 ($ millions)
Figure 37. Europe Secondary Progressive Multiple Sclerosis Drug Sales 2020-2025 (K Pcs)
Figure 38. Europe Secondary Progressive Multiple Sclerosis Drug Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales 2020-2025 (K Pcs)
Figure 40. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue 2020-2025 ($ millions)
Figure 41. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2025
Figure 42. Americas Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2025)
Figure 43. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Figure 44. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2020-2025)
Figure 45. United States Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region in 2025
Figure 50. APAC Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2020-2025)
Figure 51. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Figure 52. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2020-2025)
Figure 53. China Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. India Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. China Taiwan Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2025
Figure 61. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2025)
Figure 62. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Figure 63. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2020-2025)
Figure 64. Germany Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. France Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. UK Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Figure 71. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2020-2025)
Figure 72. Egypt Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Turkey Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug in 2025
Figure 78. Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
Figure 79. Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug
Figure 80. Channels of Distribution
Figure 81. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Forecast by Region (2026-2031)
Figure 82. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 83. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Type (2026-2031)
Figure 84. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 85. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Application (2026-2031)
Figure 86. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Application (2026-2031)
Figure 1. Picture of Secondary Progressive Multiple Sclerosis Drug
Figure 2. Secondary Progressive Multiple Sclerosis Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Secondary Progressive Multiple Sclerosis Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Secondary Progressive Multiple Sclerosis Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Secondary Progressive Multiple Sclerosis Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country/Region (2024)
Figure 10. Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of Inebilizumab
Figure 12. Product Picture of GLX-1112
Figure 13. Product Picture of DC-TAB
Figure 14. Product Picture of Etomoxir
Figure 15. Product Picture of IB-MS
Figure 16. Product Picture of Others
Figure 17. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type in 2025
Figure 18. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Type (2020-2025)
Figure 19. Secondary Progressive Multiple Sclerosis Drug Consumed in Hospital
Figure 20. Global Secondary Progressive Multiple Sclerosis Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 21. Secondary Progressive Multiple Sclerosis Drug Consumed in Clinic
Figure 22. Global Secondary Progressive Multiple Sclerosis Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 23. Secondary Progressive Multiple Sclerosis Drug Consumed in Others
Figure 24. Global Secondary Progressive Multiple Sclerosis Drug Market: Others (2020-2025) & (K Pcs)
Figure 25. Global Secondary Progressive Multiple Sclerosis Drug Sale Market Share by Application (2024)
Figure 26. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Application in 2025
Figure 27. Secondary Progressive Multiple Sclerosis Drug Sales by Company in 2025 (K Pcs)
Figure 28. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Company in 2025
Figure 29. Secondary Progressive Multiple Sclerosis Drug Revenue by Company in 2025 ($ millions)
Figure 30. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Company in 2025
Figure 31. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Secondary Progressive Multiple Sclerosis Drug Sales 2020-2025 (K Pcs)
Figure 34. Americas Secondary Progressive Multiple Sclerosis Drug Revenue 2020-2025 ($ millions)
Figure 35. APAC Secondary Progressive Multiple Sclerosis Drug Sales 2020-2025 (K Pcs)
Figure 36. APAC Secondary Progressive Multiple Sclerosis Drug Revenue 2020-2025 ($ millions)
Figure 37. Europe Secondary Progressive Multiple Sclerosis Drug Sales 2020-2025 (K Pcs)
Figure 38. Europe Secondary Progressive Multiple Sclerosis Drug Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales 2020-2025 (K Pcs)
Figure 40. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Revenue 2020-2025 ($ millions)
Figure 41. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2025
Figure 42. Americas Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2025)
Figure 43. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Figure 44. Americas Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2020-2025)
Figure 45. United States Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Region in 2025
Figure 50. APAC Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Region (2020-2025)
Figure 51. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Figure 52. APAC Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2020-2025)
Figure 53. China Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. India Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. China Taiwan Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country in 2025
Figure 61. Europe Secondary Progressive Multiple Sclerosis Drug Revenue Market Share by Country (2020-2025)
Figure 62. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Figure 63. Europe Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2020-2025)
Figure 64. Germany Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. France Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. UK Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Type (2020-2025)
Figure 71. Middle East & Africa Secondary Progressive Multiple Sclerosis Drug Sales Market Share by Application (2020-2025)
Figure 72. Egypt Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Turkey Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries Secondary Progressive Multiple Sclerosis Drug Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Secondary Progressive Multiple Sclerosis Drug in 2025
Figure 78. Manufacturing Process Analysis of Secondary Progressive Multiple Sclerosis Drug
Figure 79. Industry Chain Structure of Secondary Progressive Multiple Sclerosis Drug
Figure 80. Channels of Distribution
Figure 81. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Forecast by Region (2026-2031)
Figure 82. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 83. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Type (2026-2031)
Figure 84. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 85. Global Secondary Progressive Multiple Sclerosis Drug Sales Market Share Forecast by Application (2026-2031)
Figure 86. Global Secondary Progressive Multiple Sclerosis Drug Revenue Market Share Forecast by Application (2026-2031)
More Publications
Global Gastroenterology Electrosurgical Units (ESUs) Market Growth 2026-2032
US$ 3,660.00
July 2026
177 pages
Global Medical Shower Trolleys Market Growth 2024-2030
US$ 3,660.00
December 2024
92 pages
Global Oxygen Bag Market Growth 2024-2030
US$ 3,660.00
August 2024
108 pages
Global Insulin Patch Pump Market Growth 2024-2030
US$ 3,660.00
February 2024
114 pages
Global Fibre-Optic Laryngoscopes Market Growth 2024-2030
US$ 3,660.00
November 2024
116 pages
